HOME
|
CONTACT
About Nektar
Overview
Leadership
Management
Board of Directors
Partnering
Our Partners
Partner Case Studies
Partnering Events
Locations
Our Locations
Nektar Therapeutics Corporate Headquarters
Nektar Alabama
Nektar Therapeutics (India) Private Limited
Contact
R&D Pipeline
Products in Development
Product Pipeline
Oncology
- NKTR-102
- NKTR-105
CNS/Pain
- Oral NKTR-118 & Oral NKTR-119
Anti-Infectives
- NKTR-061 (BAY41-6551)
Clinical Trials Information
Approved Products
Scientific & Medical Event Calendar
Platform Technologies
Overview
Approved Products
Our Technology
Technology Overview
Small Molecule Polymer Conjugates
Pro-Drug Conjugates
Large Molecule Polymer Conjugates
Antibody Fragment Conjugates
Investor Relations
Overview
Financial Calendar & Presentations
News & E-mail Alerts
E-mail Alerts
Stock Information
Historic Stock Lookup
Analyst Coverage
Financial Information
SEC Filings
Annual Reports
Quarterly Results
Corporate Governance
Investor Contacts
Careers
Overview
Life at Nektar
Search Jobs
Benefits at Nektar
Overview
Benefits at San Carlos, California
Benefits at Huntsville, Alabama
Benefits at Hyderabad, India
Information for Recruiters
Career Events Calendar
See Nektar's R&D pipeline of products in clinical development »
Learn more about our clinical trials »
See Nektar partners and case studies »
News Headlines
Events Calendar
July 28, 2010
Nektar Therapeutics Q2 2010 Financial Results Call
5:00 PM Eastern Time
Listen to this webcast »
June 7, 2010
Nektar Investor Event at ASCO
Chicago, Illinois
7:30 AM – 9:15 AM
View Webcast »
Biographies of Panel Participants »
Awards & Recognitions
Jun. 2010
Dose-Escalation Phase 1 Study of NKTR-105, a Novel PEGylated Form of Docetaxel presented at the 2010 ASCO Annual Meeting by Emiliano Calvo »
Nov. 2009
Nektar in U.S. $1.5 billion licensing deal with AstraZeneca - Nature Reviews »
Sept. 28, 2009
Nektar's Next Step - BioCentury »
Site Map
Privacy
Terms of Use
Compliance Policy
Trademarks
Site Users Guide
Copyright Nektar © 2010